News & Events

Learn about what's new with CMC Biologics

Setting a Path for Growth

Thought Leadership


CMC Biologics remains vigilant in meeting customers’ growing demand for scalable biologics production. Its continued investment in technological advances, innovative facility designs and rapid facility expansions benefits customers and drives growth. CMC Biologics is dedicated to its customers’ focus to bring effective, safe medicines to patients quickly – improving lives.

Agreement with Immunocore for Process Transfer, Scale-up and Commercial-scale manufacturing of IMCgp100


Novel immunotherapeutic to be produced in CMC Biologics’ microbial facility in Copenhagen

COPENHAGEN, Denmark– 22 October 2015 – CMC Biologics, Inc., a global leader in clinical and commercial manufacturing of therapeutic proteins, today announced that they have entered into an agreement with Immunocore Limited, a leading UK-based biotechnology company focused on developing new treatments for cancer, viral infections and autoimmune diseases, for the process transfer and cGMP production of IMCgp100, Immunocore’s lead product. IMCgp100 is a novel first-in-class cancer immunotherapeutic based on proprietary platform T- cell receptor (TCR) technology.

CMC Biologics Announces Appointment of New CEO


Gustavo Mahler, COO & President at CMC Biologics, to Take the Helm January 1st 2016

Copenhagen, Denmark, Seattle, WA, and Berkeley, CA, USA – October 20, 2015 – CMC Biologics, Inc., a global leader in commercial manufacturing of therapeutic proteins with operations in Copenhagen, Denmark, Seattle, Washington and Berkeley, CA USA, announced today the promotion of Gustavo Mahler, to be effective January 1st 2016, to serve as its Chief Executive Officer. CMC Biologics, a company with 500 employees globally, is committed to delivering  world-class, fully integrated, biopharmaceutical process development and manufacturing services for clinical and commercially launched biological medicines.

Governor Inslee’s Director of Life Science and Global Health Development, Maura Little, Presides Over CMC Biologics’ Ribbon Cutting Ceremony Commemorating the Bioreactor 6Pack™ Manufacturing Facility


Innovative facility designed to deliver phase III and commercial biopharmaceutical supply to our customers globally

Seattle, WA and Berkeley, CA USA, and Copenhagen, Denmark – October 7, 2015 – CMC Biologics, Inc., a global leader in commercial manufacturing of therapeutic proteins, officially marked the opening of its first-in-class Bioreactor 6Pack™ manufacturing facility with a ribbon cutting ceremony on Thursday, October 1, at its Bothell, Washington campus. Nearly 200 local political and business leaders attended the event. 

Follow Us
Join us on LinkedIn Follow us on Twitter